Docrates Cancer Center is the first and currently the only private hospital in the Nordic countries that comprehensively specialises in cancer treatment. It operates in Helsinki, Finland. It characterises its operations as those complementing the public sector.

During the past decade, Docrates Cancer Center conducted 18 clinical trials. In the 10-year time frame, 18 clinical trials started and 7 clinical trials were completed, i.e. on average, 38.9% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 2 clinical trials were completed. i.e. 18.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Docrates Cancer Center" #1 sponsor was "Pfizer" with 4 trials, followed by "Bayer" with 3 trials sponsored, "Hoffmann-La Roche" with 3 trials sponsored, "Incyte Corporation" with 3 trials sponsored and "TILT Biotherapeutics Ltd." with 3 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Docrates Cancer Center" #1 collaborator was "Astellas Pharma Inc" with 4 trials as a collaborator, "Medivation LLC, a wholly owned subsidiary of Pfizer Inc." with 2 trials as a collaborator, "ADIR, a Servier Group company" with 1 trials as a collaborator, "CardioMed Device Consultants, LLC" with 1 trials as a collaborator and "Caris Life Sciences" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Docrates Cancer Center" are "Prostate Cancer" (5 trials), "Advanced Solid Tumors" (1 trials), "Anal Carcinoma" (1 trials), "Basal Cell Carcinoma (Unresectable or Metastatic)" (1 trials) and "Bladder Cancer" (1 trials). Many other conditions were trialed in "Docrates Cancer Center" in a lesser frequency.

Most popular intervention types in "Docrates Cancer Center" are "Drug" (20 trials), "Biological" (3 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Cisplatin" (2 trials), "Docetaxel" (2 trials), "Enzalutamide" (2 trials) and "Paclitaxel" (2 trials). Other intervention names were less common.

The vast majority of trials in "Docrates Cancer Center" are 14 trials for "All" genders, 7 trials for "Male" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Docrates Cancer Center". undefined are not yet recruiting, 7 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Docrates Cancer Center, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Docrates Cancer Center, 5 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".